News

News

Press releases

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets

Twitter

@KynTherapeutics
The people behind Kyn are drug hunters, translational researchers and #entrepreneurs who are driving toward a futur… http://iZSIcx6K1Z

@KynTherapeutics
Wonderful perspective from @Nfcanavan at @statnews on communicating #immunooncology. Yes it's complex - doesn't mea… http://WzEHJfHBOy

@KynTherapeutics
#ICYMI Our CEO @markgmanfredi, @LIMR_'s George Prendergast and other experts talk next steps in #IDO inhibition aft… http://qwyTcRKDdp

@KynTherapeutics
How much do you know about the pathways and #metabolites responsible for #immunometabolism? The players involved in… http://EkZ7sNkXuh

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn